Phase 1 dose escalation and expansion study of TROP2 CAR-engineered IL-15-transduced cord blood-derived NK cells in combination with cetuximab in patients with colorectal cancer (CRC) with minimal residual disease (MRD).
Year: 2026
Type: article
Study design: Study Protocol
Source: Journal of Clinical Oncology
Authors: Maria Pia Morelli, Rafet Basar, David Marin, Brittany E. Zeller, Jason Willis, Bryan K. Kee, Sophia Jacob, Stacy Diao, Ryan W. Huey, Van K. Morris, Alisha Heather Bent, S. Daniel Haldar, Amina Nurmammadova, Ritu Bohat, David Menter, Michael J. Overman, Xiling Shen, Scott Kopetz, Elizabeth J. Shpall, Katy Rezvani
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7122458089